Caliper sheds jobs after Zymark buy
Caliper has cut 9 per cent of its staff as part of a restructuring
exercise following its $72 million acquisition of lab automation
Bayer sales on the slide in second quarter
Bayer has reported a decline in net profits for the second quarter
of 2003, with analysts expressing concerns that litigations costs
could hold back full-year earnings.
Cambrex sells non-core business
Cambrex plans to sell off its Rutherford Chemicals business for $64
million (€56m) to allow it to focus on its human health and
Recordati planning pharmachem sale
Italy's Recordati has said that it plans to sell off its
pharmaceutical chemical activities over the next few months in
order to concentrate on pharmaceuticals.
Biotech merger wave gathers up KS Bio
KS Biomedix has confirmed that it is in negotiations that may lead
to a merger and add to the mini-wave of consolidation sweeping over
the UK industry.
Roche buys its way out of diagnostics trouble
Roche has moved to settle its long-running legal dispute with
USA-based Igen by acquiring the firm in a deal valued at around
$1.4 billion (€1.22bn).
Pharma holds back life sciences at DSM
DSM reports a disappointing set of second quarter results and says
it is unlikely to meet its 2002 operating profit level this year;
the group blames weaker demand for its products and negative
currency factors. Restructuring drive...
Baxter wins court order in Bayer espionage case
A judge has ordered an employee at Bayer's US subsidiary to hand
files over to the court in a lawsuit brought by Baxter alleging
Baxter accuses former employee of espionage
Baxter has filed a lawsuit in the USA alleging that one of its
former employees provided proprietary manufacturing information to
rival company Bayer.
Pharma's focus on growth "unsustainable" says report
The pharmaceutical industry is failing to increase efficiencies in
core areas of its business - such as clinical trials and sales -
because of an enormous pressure from investors to drive revenues,
according to Datamonitor.
Lonza revamp comes too late for first-half figures
The difficulties facing Lonza came into clear focus today as the
company published its half-year results, with sales down across its
custom manufacturing, organic chemicals and polymers businesses.
BASF buys pharma chemical firm
Chemical major BASF has expanded the range of products it offers to
pharmaceutical clients with the $65 million (€58m) purchase of
Callery Chemical from Mine Safety Appliances.
Akzo results better than expected
Akzo Nobel's second-quarter results reveal increasing pressure on
its drugs business and lead to speculation that it may consider a
Galen says takeover talks break down
Galen Holdings of the UK has called an end to talks with an unnamed
buyer, thought to have been US generics specialist Barr
Sheep cull follows staff cuts at PPL
Scotland's PPL has started a mass slaughter of its flock of sheep
engineered to produce alpha-1 antitrypsin in their milk. The cull
could spell the end of the firm's ambitions in transgenic